Spotlight on Nephrology

Credits: 0.5 CME / CNE / CPE
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Successful Initiation of Pharmacologic Therapy for ADPKD
Neera Dahl, MD, PhD
Medical Education Resources (MER)

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Successful Initiation of Pharmacologic Therapy for ADPKD

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Describe the optimal use of REMS programs to improve safety and patient outcomes.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Initiating pharmacologic therapy
  • REMS rationale and objectives for treatment of ADPKD
  • Strategies for patient counseling
  • Teamwork and collaboration: patient, nephrologist, pharmacist, and other health care providers

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Lena DeVietro, PharmD
Dr. DeVietro has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-174-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Describe the optimal use of REMS programs to improve safety and patient outcomes.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Initiating pharmacologic therapy
  • REMS rationale and objectives for treatment of ADPKD
  • Strategies for patient counseling
  • Teamwork and collaboration: patient, nephrologist, pharmacist, and other health care providers

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Lena DeVietro, PharmD
Dr. DeVietro has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-174-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Nephrology Presentations

0.75 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Redefining the Management of CMV in SOT: Emerging Options for High-Risk Patients: A Care Team Forum℠

Start

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

Activity Details

Free CME/MOC/CNE/CPE
0.75 AMA PRA Category 1 Credit(s)
0.75 ABIM MOC Point(s)
0.75 ANCC Contact Hour(s)
0.75 ACPE Contact Hour(s)
Released: July 7, 2021
Expires: July 6, 2022
45 minutes to complete

Accredited By

Provided by RMEI Medical Education, LLC

Target Audience

Clinicians who diagnose and manage patients with cytomegalovirus (CMV) infection and disease.

Learning Objectives

After completing this activity, the clinician should be able to:

  • Summarize existing and emerging therapies for the prevention and treatment of cytomegalovirus (CMV) disease in solid organ transplant (SOT) patients
  • Manage adverse effects of antiviral therapies, including bone marrow and renal toxicities
  • Identify risk factors and emerging therapies for resistant CMV disease

Activity Description

This activity will bring you face-to-face with Drs. Kotton, Silveira, and Pereira as they discuss the many facets of cytomegalovirus (CMV) infection in solid organ transplant (SOT) patients. They will share clinical insights on emerging treatments for resistant and refractory CMV disease, as well as tips for avoiding and managing the challenging side effects of current antiviral therapies. You will be captivated as you watch a first-hand account of life-altering CMV when a lung transplant patient shares his journey with resistant CMV, how CMV treatments and side effects impacted his life, and his advice for healthcare professionals.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, MA


Marcus Pereira, MD, MPH, FAST
Assistant Professor of Medicine
Medical Director, Transplant Infectious Disease Program
Columbia University Medical Center
New York, NY


Fernanda P. Silveira, MD, MS, FIDSA, FAST
Associate Professor of Medicine
Director of Clinical Operations, Transplant Infectious Diseases
University of Pittsburgh
University of Pittsburgh Medical Center
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Camille Nelson Kotton, MD, FIDSA, FAST, has affiliations with Hookipa, Merck, Shire/Takeda (Consultant).

Marcus Pereira, MD, MPH, FAST, has no relevant financial relationships with ineligible companies to disclose.

Fernanda P. Silveira, MD, MS, FIDSA, FAST, has affiliations with Ansun, Merck, Slieagen, Takeda (Grant/Research Support).

Patient
Patient participating in this activity has no relevant financial relationships with ineligible companies to disclose.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.75 contact hour(s) (0.75 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-002-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.
For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED
INTO A DRAWING FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a full-service medical education company. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For questions regarding this activity, please contact Linda Hopkins at lhopkins@rmei.com

0.5 CME / CNE / CPE
Medical Education Resources (MER)
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Monitoring and Risk Mitigation

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Monitoring and Risk Mitigation

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Employ strategies to mitigate risk when initiating and monitoring pharmacologic therapy for ADPKD.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the third of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Milestones and steps for REMS requirements
  • Mitigation elements
    • Laboratory monitoring
  • Enhancing adherence in patients with ADPKD
  • REMS and COVID-19

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-175-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Employ strategies to mitigate risk when initiating and monitoring pharmacologic therapy for ADPKD.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the third of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Milestones and steps for REMS requirements
  • Mitigation elements
    • Laboratory monitoring
  • Enhancing adherence in patients with ADPKD
  • REMS and COVID-19

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-175-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

0.5 CME / CNE / CPE
Medical Education Resources (MER)
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Successful Initiation of Pharmacologic Therapy for ADPKD

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Successful Initiation of Pharmacologic Therapy for ADPKD

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Describe the optimal use of REMS programs to improve safety and patient outcomes.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Initiating pharmacologic therapy
  • REMS rationale and objectives for treatment of ADPKD
  • Strategies for patient counseling
  • Teamwork and collaboration: patient, nephrologist, pharmacist, and other health care providers

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Lena DeVietro, PharmD
Dr. DeVietro has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-174-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Describe the optimal use of REMS programs to improve safety and patient outcomes.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the second of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Initiating pharmacologic therapy
  • REMS rationale and objectives for treatment of ADPKD
  • Strategies for patient counseling
  • Teamwork and collaboration: patient, nephrologist, pharmacist, and other health care providers

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Lena DeVietro, PharmD
Multi-Specialty Clinical Pharmacist
Yale New Haven Hospital
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Lena DeVietro, PharmD
Dr. DeVietro has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-174-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

0.5 CME / CNE / CPE
Medical Education Resources (MER)
Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Patient Selection and Individualization

Optimal Pharmacologic Treatment of ADPKD: What You Need to Know - Patient Selection and Individualization

Start

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Assessing risk for rapid progression of ADPKD
    • Imaging modalities
    • Criteria and predictors
    • Mayo classification model and others
  • Clinical trials in pharmacologic treatment of ADPKD
    • Efficacy and safety
  • Patient selection
  • REMS and other considerations before initiating therapy

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Gary Israel, MD
Dr. Israel has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-173-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

Activity Details

Free CME/CNE/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: February 19, 2021
Expires: February 19, 2022
30 minutes to complete

Jointly Provided By

This activity is jointly provided by Medical Education Resources and CMEology.

Target Audience

The accredited activity is intended for nephrologists, nurse practitioners, physician assistants, specialty pharmacists, and other health care providers who care for patients with ADPKD.

Learning Objective

Apply evidence-based principles to select patients with ADPKD who are appropriate for disease-modifying therapy.

Activity Description

The advent of pharmacologic therapy for ADPKD offers new opportunities to delay the progression of renal decline for patients. However, health care providers need to know how to identify patients at high risk of progression when considering therapy and how to manage patients receiving disease-modifying therapy.

This is the first of three related activities on the pharmacologic management of patients with ADPKD. The activities follow a patient with ADPKD through her journey from diagnosis to consideration of therapy, initiation of treatment, and risk mitigation. In each 0.5-hour continuing education activity, internationally renowned faculty will provide key insights into assessing candidates for therapy, managing ongoing care, and employing strategies to mitigate risks. Additionally, a patient with ADPKD will provide a first-person perspective on the experience of undergoing treatment. This multimedia activity consists of a case study with text, faculty and patient videos, and evidence-based animated slides with narration. The activity is interactive, and the learner can advance through the material at their desired pace.

Statement of Educational Need

Until recently, management of patients with ADPKD was limited to supportive measures. Advances in the understanding of ADPKD pathophysiology have led to the development of disease-modifying therapy. Health care providers may not be aware of the criteria for treatment initiation and selection of the best patients for therapy as well as safety monitoring. Use of tolvaptan to delay ADPKD progression requires participation in a Risk Evaluation and Mitigation Strategy to ensure that the benefits of therapy outweigh the risks. This activity will help health care providers to understand pivotal clinical considerations before and after initiation of pharmacologic therapy.

Agenda

  • Assessing risk for rapid progression of ADPKD
    • Imaging modalities
    • Criteria and predictors
    • Mayo classification model and others
  • Clinical trials in pharmacologic treatment of ADPKD
    • Efficacy and safety
  • Patient selection
  • REMS and other considerations before initiating therapy

Activity Chair

Neera Dahl, MD, PhD
Associate Professor
Director of Clinical Trials
Section of Nephrology
Department of Medicine
Yale University School of Medicine
New Haven, Connecticut

Faculty

Gary Israel, MD
Section Chief: Abdomen
Professor of Radiology
Yale University School of Medicine
New Haven, Connecticut

Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all of its educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Neera Dahl, MD, PhD (Activity Chairperson)
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Otsuka Pharmaceutical, Inc.

Serve(d) as a speaker or a member of a non-branded speakers bureau for: Otsuka Pharmaceutical, Inc.

Gary Israel, MD
Dr. Israel has no relationships to disclose.

CMEology planners have no relationships to disclose.
MER content reviewers have no relationships to disclose.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Medical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This CE activity provides 0.5 contact hour(s) of continuing nursing education.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Accreditation Council for Pharmacy EducationMedical Education Resources (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MER designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number - 0816-9999-20-173-H01-P)

This activity is certified as Knowledge-based CPE.

Instructions for Receiving Credit

There are no fees for participating in and receiving credit for this activity. During the period February 19, 2021 through February 19, 2022, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest.

Statement of Commercial Support

This activity is supported by an independent educational grant from Otsuka America Pharmaceutical, Inc.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the planners. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For questions about this activity, please contact CMEology at: info@cmeology.org or Medical Education Resources at: http://cmepartner.org/contact.

0.50 CME / CE
Clinical Care Options
Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Start

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com